Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Motzer RJ, Albiges L, Treviño Aguirre SA, Kanesvaran R, Centkowski P, Reimers MA, Sade JP, Pouessel D, Biscaldi E, Esteban E, Arranz Arija JÁ, Tykodi SS, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun DA, Powles T, Choueiri TK

Open source

DOI: 10.1016/j.annonc.2026.02.011
Published: 2026 Jun
Container: Annals of oncology : official journal of the European Society for Medical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.02.011,
  title = {Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.},
  author = {Motzer RJ and Albiges L and Treviño Aguirre SA and Kanesvaran R and Centkowski P and Reimers MA and Sade JP and Pouessel D and Biscaldi E and Esteban E and Arranz Arija JÁ and Tykodi SS and van Kooten Losio M and Dighe A and Ma H and Valmeekam V and Simmons A and Scheffold C and Andrianova S and Braun DA and Powles T and Choueiri TK},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.02.011},
  url = {https://doi.org/10.1016/j.annonc.2026.02.011}
}

RIS

TY  - JOUR
TI  - Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
AU  - Motzer RJ
AU  - Albiges L
AU  - Treviño Aguirre SA
AU  - Kanesvaran R
AU  - Centkowski P
AU  - Reimers MA
AU  - Sade JP
AU  - Pouessel D
AU  - Biscaldi E
AU  - Esteban E
AU  - Arranz Arija JÁ
AU  - Tykodi SS
AU  - van Kooten Losio M
AU  - Dighe A
AU  - Ma H
AU  - Valmeekam V
AU  - Simmons A
AU  - Scheffold C
AU  - Andrianova S
AU  - Braun DA
AU  - Powles T
AU  - Choueiri TK
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.02.011
UR  - https://doi.org/10.1016/j.annonc.2026.02.011
ER  -

APA

RJ, M., L, A., SA, T. A., R, K., P, C., MA, R., JP, S., D, P., E, B., E, E., JÁ, A. A., SS, T., M, V. K. L., A, D., H, M., V, V., A, S., C, S., S, A., DA, B., T, P., & TK, C. (2026). Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.02.011

Source records

pubmed · retrieved 2026-09-25T20:26:13.564Z